Multi-center, randomized, double-blind, parallel-group study to confirm superiority of KLH-2109 to placebo in uterine fibroids patient with menorrhagia and pain
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administration
Timeframe: Up to 12 weeks
Proportion of women with a maximum NRS for pain score of 1 or less during 28 days before the end of study drug administration
Timeframe: Up to 12 weeks